Champions Oncology, Inc. Stock price

Equities

CSBR

US15870P3073

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.94 USD -1.59% Intraday chart for Champions Oncology, Inc. -10.18% -12.10%
Sales 2024 * 48.84M Sales 2025 * 53.68M Capitalization 67.15M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 1.37 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.25 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.59%
1 week-10.18%
Current month-16.27%
1 month-11.31%
3 months-6.70%
6 months-14.53%
Current year-12.10%
More quotes
1 week
4.93
Extreme 4.93
5.40
1 month
4.89
Extreme 4.8856
6.25
Current year
4.89
Extreme 4.8856
7.13
1 year
4.02
Extreme 4.02
7.32
3 years
3.75
Extreme 3.75
13.14
5 years
3.75
Extreme 3.75
14.68
10 years
1.11
Extreme 1.11
17.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 10-10-25
President - 23-10-16
Chairman 59 10-10-25
Members of the board TitleAgeSince
Founder 64 07-12-31
Director/Board Member 53 11-06-26
Chairman 59 10-10-25
More insiders
Date Price Change Volume
24-03-27 4.94 -1.59% 937
24-03-26 5.02 -3.46% 5,272
24-03-25 5.2 -3.70% 6,935
24-03-22 5.4 +1.50% 4,202
24-03-21 5.32 -3.27% 2,383

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverages the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.94 USD
Average target price
6 USD
Spread / Average Target
+21.46%
Consensus
  1. Stock
  2. Equities
  3. Stock Champions Oncology, Inc. - Nasdaq